Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Operating Expenses (2022 - 2025)

Historic Operating Expenses for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $48.7 million.

  • Entrada Therapeutics' Operating Expenses rose 1803.87% to $48.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $183.1 million, marking a year-over-year increase of 1627.7%. This contributed to the annual value of $163.8 million for FY2024, which is 2390.47% up from last year.
  • Latest data reveals that Entrada Therapeutics reported Operating Expenses of $48.7 million as of Q3 2025, which was up 1803.87% from $48.8 million recorded in Q2 2025.
  • Entrada Therapeutics' Operating Expenses' 5-year high stood at $48.8 million during Q2 2025, with a 5-year trough of $22.2 million in Q1 2022.
  • Moreover, its 4-year median value for Operating Expenses was $36.9 million (2023), whereas its average is $35.5 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 4616.66% in 2023, then skyrocketed by 1142.16% in 2025.
  • Entrada Therapeutics' Operating Expenses (Quarter) stood at $25.6 million in 2022, then soared by 44.43% to $36.9 million in 2023, then increased by 17.11% to $43.3 million in 2024, then grew by 12.48% to $48.7 million in 2025.
  • Its Operating Expenses stands at $48.7 million for Q3 2025, versus $48.8 million for Q2 2025 and $42.3 million for Q1 2025.